Ocugen, Inc. OCGN
Regular-session close
After hours · Nov 16, 7:21 PM ET
- YTD
- -42.74%
- 1 year
- -35.04%
Discussion (3611)
That’s you chance to make money if you buy 3,000 shares where you gonna make 1,00,000 $ a year be smart do research and see it will go up to 38$
I bought MSTR at 700$ when it went down to 1230 people was scared i bought more now I made 500$ on the top of 1,230 just time and patience you gonna be a winner
Never to late to buy it’s still cheap
With in 3 months it went up 312%
I have lots of time it will go with in 12 months to 38$ I have 3,000 shares I’ll make 100,000 $ no rush
Don’t sell it’s very good company it will go mach higher
Ocugen (OCGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $7.00 price target.
Ocugen (OCGN) was up more than 11% after a federal appeals court upheld a lower-court decision, dismissing allegations of misleading shareholders with its statements about a prospective COVID-19 vaccine and its approvals in the US.
03:37 PM EDT, 03/22/2024 (MT Newswires) -- Ocugen (OCGN) shares surged nearly 19% Friday, a day after a federal appeals court upheld a lower-court decision, dismissing allegations of misleading shareholders with its statements about a prospective COVID-19 vaccine and its approvals in the US.
Plaintiffs alleged that Ocugen made statements suggesting the US Food and Drug Administration would approve its Covaxin vaccine candidate based on results from trial conducted in India. The agency in June 2021 instead said Ocugen would need to start US trials, sending its shares plunging.
The US Court of Appeals for the Third Circuit ruled the company provided ample warning about the risks with FDA approval, writing that using facts that only became known later "does not substitute for contemporaneous knowledge in a securities fraud case."
Price: 1.59, Change: +0.25, Percent Change: +18.75
